It may be rethinking a notable acquisition, but Roth analyst Bill Kirk still thinks there is money to be made on High Tide (High Tide Stock Quote, Chart, News, Analysts, Financials NASDAQ:HITI).
On February 25, HITI reported that its previously announced entry into the German market -via thw acquisition of 51% of Purecan GmbH- was on hold and that the company would explore “alternative arrangements”.
Kirk says the move is a political one and believes that HITI is still operating from a position of strength.
“After the February 23rd German election result – the CDU’s Merz is set to take the chancellor role (historically anti-cannabis party), and HITI has decided to reassess the terms of its planned acquisition of Purecan,” he explained. “We believe the regulatory environment remains positive for medical cannabis, but general access (telemedicine, prescription regulations etc.) is now less certain under new leadership. Given the election results, we believe High Tide is prudent to reassess, particularly as it pertains to the upfront costs, and its deal with Purecan. We believe their proof of concept remains compelling, with a strong Canadian LP interest ready for the German market. While the outcome of the election may delay longer term cannabis reform in Germany, HITI may be able to leverage the situation to facilitate an improved risk/reward entry into the market.”
In a research update to clients February 25, Kirk maintained his “Buy” rating and price target of $4.50 on HITI.
The analyst thinks the company will post EBITDA of $33.5-million on revenue of $583.0-million in fiscal 2025.
“With HITI having the leverage, we believe management could re-structure the deal to look more like a JV or a profit sharing agreement, without having to pay the €4.8M fee up front,” Kirk added. “We do not believe HITI is required to pay Purecan a fee to begin renegotiation. HITI’s balance sheet is well positioned, but this would be an opportunity to preserve some cash while still gaining exposure into what could become a significant cannabis market longer term.”
Following the company's fourth quarter results, Beacon analyst Russell Stanley has lowered his price target on Green Thumb Industries (Green… [Read More]
Its fourth quarter results are in the books and Ventum Capital Markets analyst Amr Ezzat still thinks there is money… [Read More]
He's still bullish, just a little less so. That's RBC analyst Darko Mihelic's take on EQB Inc. (EQB Stock Quote,… [Read More]
After a meeting with the company, National Bank Financial analyst Richard Tse remains bullish on Shopify (Shopify Stock Quote, Chart,… [Read More]
Following results that have sent the stock northward, Research Capital analyst Andre Uddin remains bullish on Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals… [Read More]
Good company, fully valued stock. That's the takeaway from Roth Capital analyst Matt Koranda, who launched coverage of Warby Parker… [Read More]